In this piece, we discuss the 11 Most Volatile Stocks Under $5 for Day Trading.
Morningstar released its Q1 2026 U.S. Stock Market Outlook report last month. Led by Chief U.S. Economist Preston Caldwell and Chief U.S. Market Strategist David Sekera, the discussions made a case for volatility, which is expected to surpass the levels seen in 2025.
First, Sekera highlighted the sharp swings seen in early 2025 due to concerns related to DeepSeek and tariffs. Secondly, he described the second half of the year as relatively stable. However, he projects higher volatility in 2026, attributing this to elevated valuations, concentrated mega-cap influence, shifting monetary policy, trade negotiations, political uncertainty, and tightening credit conditions. He also touched upon overvalued stocks, which he believes could experience further and faster declines. Moreover, he said, leading AI stocks remain susceptible to sharp declines if they fail to meet expectations.
At the same time, Caldwell highlighted resilience shown in the previous year’s GDP growth, yet expressed his belief that uncertainty surrounding tariffs, consumption trends, underutilized labor capacity, and inflation dynamics remain key concerns in 2026.
Amid a macro environment marked by elevated valuations, tightening spreads, and broader uncertainty, volatility remains a key driver for active traders focused on price swings. With 2026 expected to be a year of sharp moves, in this list, we will highlight the most volatile stocks under $5 for day trading.
Stock market data. Photo by Alesia Kozik on Pexels
Our Methodology
To curate our list of the 7 most volatile stocks under $5 for day trading, we used a screener to identify companies with a share price under $5.00, an equity beta above 2.0, and an average daily trading volume of at least 1 million shares. In addition, to assess consistent volatility, we narrowed down the list to stocks featuring an average daily trading range of over 5%.
Finally, we ranked the shortlisted stocks in ascending order by the number of hedge funds that are bullish on each stock. To assess hedge fund sentiment, we used Insider Monkey’s hedge fund database, which tracks 978 stocks as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
7. Caribou Biosciences, Inc. (NASDAQ:CRBU)
Number of Hedge Fund Holders: 19
Caribou Biosciences, Inc. (NASDAQ:CRBU) is included in our list of the 7 most volatile stocks under $5 for day trading.
On February 2, 2026, Clear Street began covering Caribou Biosciences, Inc. (NASDAQ:CRBU) with a ‘Buy’ rating and a $13 price target. The firm’s bullish stance was attributed to the company’s off-the-shelf allogeneic CAR-T program, which was described as the primary value generator. The investment bank projected 2040 peak sales of $992 million with a 30% chance of success for the lead candidate, vispa-cel. Caribou is preparing to begin a registrational Phase 3 trial in second-line or later large B-cell lymphoma. Additionally, with a 20% chance of success, Clear Street forecasts that CB-011 may reach $734 million in peak 2040 sales, highlighting both clinical risk and upside potential.
On January 6, 2026, BofA cited a wider reset in U.S. biopharma valuations, cutting its price target on Caribou Biosciences, Inc. (NASDAQ:CRBU) from $8 to $6 while keeping a ‘Buy’ rating. Although durability remains the main point of contention for investors, the investment firm argued that better access to capital, M&A activity, and encouraging data catalysts indicate a biotech turnaround.
Caribou Biosciences, Inc. (NASDAQ:CRBU) focuses on advancing an internal oncology pipeline and supporting broader therapeutic and biotech research uses by leveraging CRISPR genome-editing technology to develop off-the-shelf CAR-T and CAR-NK cell treatments.
6. Bit Digital, Inc. (NASDAQ:BTBT)
Number of Hedge Fund Holders: 20
Bit Digital, Inc. (NASDAQ:BTBT) is one of the 7 most volatile stocks under $5 for day trading.
Bit Digital, Inc. (NASDAQ:BTBT), on February 6, 2026, released January Ethereum treasury numbers, which reflect both volatility and size risk.
On January 31, 2026, Bit Digital, Inc. (NASDAQ:BTBT) had 155,239.4 ETH, which was worth around $380.2 million at a closing price of $2,449, compared to an average acquisition cost of roughly $3,045 at that time. By staking about 138,266 ETH, or 89% of holdings, the company generated rewards of 344.0 ETH throughout the month, resulting in an annualized yield of about 2.9%. As of January 31, 2026, there were 324,202,059 shares outstanding.
In addition to exposure to cryptocurrency, management is reinforcing its equity strategy. On January 29, 2026, Bit Digital, Inc. (NASDAQ:BTBT) reiterated that, even after the IPO lockup expires on February 2, 2026, it will not sell its roughly 27.0 million WhiteFiber (WYFI) shares. These holdings had a market value of over $527.6 million as of January 31, 2026, which was more than the value of its ETH treasury. Accordingly, the company maintains WhiteFiber’s position as a key balance-sheet pillar.
Bit Digital, Inc. (NASDAQ:BTBT) provides digital asset mining, Ethereum staking, AI-focused cloud computing, and colocation services. The company combines crypto treasury exposure and infrastructure platforms to diversify income in the blockchain and high-performance computing industries.
5. C4 Therapeutics, Inc. (NASDAQ:CCCC)
Number of Hedge Fund Holders: 21
C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading.
As of February 16, 2026, all of the analysts who cover C4 Therapeutics, Inc. (NASDAQ:CCCC) remain bullish on the stock. Their consensus price target of $7.00 indicates a 270.37% upside, which reflects their belief in Cemsidomide, the company’s primary degrader.
On January 14, 2026, C4 Therapeutics, Inc. (NASDAQ:CCCC) laid out key clinical and regulatory milestones through 2028, including plans to achieve accelerated approval for Cemsidomide in relapsed/refractory multiple myeloma.
With an NDA submission targeted by year-end 2028 and initial ORR data anticipated in 2H 2027, C4 Therapeutics, Inc. (NASDAQ:CCCC) intends to launch the Phase 2 MOMENTUM trial in Q1 2026 for patients who are fourth-line or later. In patients with second-line or later disease, a Phase 1b combination study involving elranatamab is scheduled to start in Q2 2026, while a Phase 3 trial is anticipated by early 2028.
Based on 2025 Phase 1 data, Cemsidomide showed ORRs of 40% and 53% at 75 µg and 100 µg, respectively. With partnerships with Merck KGaA, Roche, and Biogen, C4T hopes to file up to 3 INDs by 2028 from its neuro- and inflammation programs, in addition to its oncology programs.
C4 Therapeutics, Inc. (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, uses its Degronimid platform to develop small-molecule degraders that selectively eliminate disease-driving proteins in neurodegenerative, inflammatory, and cancerous diseases.
4. Outset Medical, Inc. (NASDAQ:OM)
Number of Hedge Fund Holders: 23
Outset Medical, Inc. (NASDAQ:OM) is one of the 7 most volatile stocks under $5 for day trading.
On February 12, 2026, Outset Medical, Inc. (NASDAQ:OM) shares received fresh support from analysts despite a decline in price targets after fourth-quarter results that largely met expectations. After the company provided what it considered to be a realistic 2026 target, TD Cowen lowered its target to $12 from $15, and BTIG lowered its target to $15 from $17, both of which kept their ‘Buy’ ratings.
In a research note, the BTIG analyst informed investors that this quarter, featuring a stable sales force, an upcoming product, a wide and expanding deal pipeline, robust recurring revenue, and improving margins, will help the company restore credibility.
Outset Medical, Inc. (NASDAQ:OM), on February 11, 2026, announced fourth-quarter revenue of $28.90 million, a 2% year-over-year decrease. Accordingly, the total revenue for 2025 came out at $119.50 million, a 5% increase. In addition, the full-year margin improved to 39.10%, and the quarterly gross margin increased by 600 basis points to 42.40%.
Meanwhile, cash at year-end was $173 million, and adjusted net loss decreased from $19.30 million to $15.10 million. In addition to outlining plans to launch its next-generation Tablo platform in the second quarter, Outset Medical, Inc. (NASDAQ:OM)’s management projected 2026 revenue of $125 million to $130 million, with a non-GAAP gross margin in the low-to-mid-40% range.
Outset Medical, Inc. (NASDAQ:OM), founded in 2003 in San Jose, offers dialysis solutions through its Tablo Hemodialysis System, which enables both acute and home treatment. The company aims to simplify and modernize dialysis care delivery.
3. Opendoor Technologies Inc. (NASDAQ:OPEN)
Number of Hedge Fund Holders: 30
Opendoor Technologies Inc. (NASDAQ:OPEN) is one of the 7 most volatile stocks under $5 for day trading.
As of February 16, 2026, Opendoor Technologies Inc. (NASDAQ:OPEN)’s shares had climbed over 190% over last year and more than 80% in the last six months, indicating investor interest despite persistent operational concerns.
On February 9, 2026, UBS described the most recent earnings as another reset point, raising its price target on Opendoor Technologies Inc. (NASDAQ:OPEN) from $1.60 to $5.00 while keeping a ‘Neutral’ rating. The firm noted that Opendoor still needs to demonstrate that it can consistently produce positive unit economics in light of a steep drop in revenue and increased EBITDA losses. The next earnings report, which is due on February 19, will continue to be closely watched for profitability and margins.
Prior to this, on January 20, 2026, Deutsche Bank maintained a ‘Hold’ rating on Opendoor Technologies Inc. (NASDAQ:OPEN) while raising its target from $0.90 to $4.00. As the iBuyer model tackles the volatile housing environment, the updates collectively imply that analysts recognize improved sentiment and valuation recalibration but continue to exercise caution regarding execution risk.
Opendoor Technologies Inc. (NASDAQ:OPEN) operates a digital platform for buying and selling residential real estate, leveraging data-driven pricing and streamlined transactions to provide homeowners with liquidity and convenience across the United States.
2. Aurora Innovation, Inc. (NASDAQ:AUR)
Number of Hedge Fund Holders: 39
Aurora Innovation, Inc. (NASDAQ:AUR) is included in our list of the 7 most volatile stocks under $5 for day trading.
On February 12, 2026, despite the company’s minimal current revenue, Cantor Fitzgerald maintained its ‘Overweight’ rating and $12.00 price target for Aurora Innovation, Inc. (NASDAQ:AUR). With this update, the investment firm expressed its confidence in the company’s trajectory toward autonomous trucking.
Since commercialization started in late April, Aurora Innovation, Inc. (NASDAQ:AUR) has accumulated more than 4.5 million autonomous miles, including more than 250,000 fully driverless miles. This achievement positions the company as a leader in self-driving freight, according to Cantor.
However, the early-stage monetization profile was highlighted by the $2.00 million in revenue over the previous 12 months. By the end of 2026, management plans to have more than 200 driverless trucks, roughly matching Cantor’s previous estimate of 207 units, up from 10 as of December. The investment firm expressed confidence in Aurora Innovation, Inc. (NASDAQ:AUR)’s goal to achieve positive free cash flow in fiscal 2028 and breakeven (gross margins) by the end of fiscal 2026. With production scheduled to begin in 2027, Aurora’s exclusive partnership with Continental AG is seen as a crucial catalyst for scaling.
Aurora Innovation, Inc. (NASDAQ:AUR), headquartered in Pittsburgh, develops the Aurora Driver, integrating hardware, software, and data services to enable autonomous vehicle operation, with a focus on long-haul trucking and logistics markets.
1. Peloton Interactive, Inc. (NASDAQ:PTON)
Number of Hedge Fund Holders: 62
Peloton Interactive, Inc. (NASDAQ:PTON) is one of the 7 most volatile stocks under $5 for day trading.
Analyst sentiment surrounding Peloton Interactive, Inc. (NASDAQ:PTON) remains moderately strong as of February 16, 2026, with roughly 50% of analysts covering the stock remaining bullish on it. The consensus price target of $7.00 implies a 64.70% upside potential.
On February 12, 2026, Ronald Josey, a Citi analyst, reduced the firm’s price target on Peloton Interactive, Inc. (NASDAQ:PTON) from $8.25 to $5.00, while keeping a ‘Neutral’ rating. He cited higher churn after recent price increases, even though operational improvements were noted.
Additionally, on February 10, 2026, Argus lowered Peloton Interactive, Inc. (NASDAQ:PTON) from ‘Buy’ to ‘Hold’, citing softening demand trends for the company’s online cycling classes and the intense competition from gyms and at-home fitness providers.
Prior to this, on February 6, 2026, analyst Eric Sheridan of Goldman Sachs lowered the price target on Peloton Interactive, Inc. (NASDAQ:PTON) from $12.50 to $7.00, while maintaining a ‘Buy’ rating. Sheridan cited strong adjusted EBITDA from cost optimization but disappointing hardware sales, leading to a downward revision to 2H26 revenue.
Peloton Interactive, Inc. (NASDAQ:PTON) provides technology-enabled at-home fitness, including connected bikes, treadmills, and subscription-based live and on-demand classes, while also fostering a community-focused ecosystem through its Connected Fitness Products and Subscription segments.
While we acknowledge the potential of PTON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PTON and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 14 Oversold Value Stocks to Invest in Right Now and Cathie Wood’s 10 Stock Picks with Huge Upside Potential.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
